AMGN at a glance
Amgen (AMGN, SEC CIK 318154) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Amgen (AMGN) reported revenue of $36.8 billion (up 10.0% from FY2024) and net income of $7.7 billion. Diluted EPS was $14.23.
- As of September 30, 2026, 63 institutional investment managers tracked by SignalX reported holding Amgen (AMGN) shares worth $89.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Khosla Rachna on August 13, 2026 of 1,252 shares at $416.43 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $36.8B
- +10.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 63 funds
- $89.8B · −1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical company focused on innovative therapies for serious illnesses
- NEW segment emphasis: Integration and conversion of Horizon Therapeutics' equity plans post-acquisition in October 2023
- Strategic shift: Acquisition of Horizon Therapeutics with stock plans merged, ending Horizon plans for future grants as of Oct 6, 2023
- Quantitative metric: 11,230,989 total securities issuable under Amgen and acquired equity plans, weighted-average exercise price $234.45
- Noteworthy fact: Performance units granted in 2023-2025 can yield up to 200% of target shares based on performance goals
Management Discussion & Analysis
- Cash and equivalents $9.1B in 2025 vs $12.0B in 2024, decline of $2.9B
- Long-term debt decreased to $50.0B in 2025 from $56.5B in 2024
- Dividends per share increased 6% YoY to $2.38 in 2025 from $2.25 in 2024
- No stock repurchases in 2025, $200M repurchased in 2024, $6.8B repurchase authorization remains
- Management confident in liquidity from operations, debt markets, and existing cash for capital needs and shareholder returns
Risk Factors
- Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages
- Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals
- Supply chain/operational vulnerability: Multi-jurisdictional patent litigation delays marketing; UPC actions and EPO oppositions prolong product launches like Repatha and PAVBLU
- Competitive risk: Multiple biosimilar patent infringement lawsuits filed against five companies including Amneal, Hikma, Dr. Reddy’s, Alkem seeking to enter U.S. market for Prolia/XGEVA
- Financial risk: $1.8B final U.S. repatriation tax payment made in 2025 under 2017 Tax Act, material cash outflow impacting liquidity planning
AI summary of the AMGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $10,365M, up 8% YoY from $9,557M, driven by product-sales volume growth
- Operating margin 35.8% vs 26.4% YoY, with operating income $3,710M vs $2,526M
- Best product: Repatha $1,085M, worst: Prolia $1,139M, down 45% YoY amid biosimilar competition
- Cash $13,190M vs $9,129M at December 31, 2025, with nine-month operating cash flow $10,432M vs $8,355M
- Outlook: volume growth offset by net-price declines, with continued Prolia and XGEVA erosion from biosimilars
Risk Factors
- TAVNEOS withdrawal risk: FDA proposed revoking U.S. approval after liver-injury concerns and questioned ADVOCATE data reliability
- TAVNEOS international risk: European Commission revoked authorization in August 2026, with other regulators restricting or reviewing use
- Medicare pricing pressure: CMS pricing reduced ENBREL profitability from January 1, 2026, with Otezla pricing beginning January 2027
- State reimbursement risk: Colorado established an ENBREL upper payment limit effective no earlier than January 1, 2027
- Regulatory capacity risk: FDA staffing and budget reductions could delay application reviews and approvals
AI summary of the AMGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month 2026 unaudited results, plus September 30 financial position, announced November 3, 2026
- Exhibit 99.1 contains the earnings release with GAAP results and non-GAAP reconciliations
Item EX-99.1: Item EX-99.1
- Q3 revenue $10.4B, up 8%, with product sales up 8% on volume growth and 17 products posting double-digit growth
- GAAP EPS $7.08, up 19%, while operating margin expanded 9.9 points to 37.5%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- David W. Gibbs appointed director effective October 26, 2026, expanding the Board to 13 directors
- Board remains highly independent: 12 of 13 directors independent
Item EX-99.1: Item EX-99.1
- David W. Gibbs appointed immediately to Amgen’s Board, expanding oversight and consumer-brand expertise
- Gibbs joins Audit Committee and Compensation and Management Development Committee
Item 2.02: Results of Operations and Financial Condition
- Q2 and six-month 2026 unaudited results, plus June 30 financial position, announced August 4, 2026
- Investors must review Exhibit 99.1 for revenue, earnings, cash flow and balance-sheet figures
Item EX-99.1: Item EX-99.1
- Q2 revenue $10.1B, up 10%, with product sales up 9% and six growth drivers up 26%, supporting continued portfolio momentum
- GAAP EPS $4.37, up 65%, while non-GAAP EPS $6.29, up 4%, reflecting higher expenses and tax pressure
AI summaries of AMGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AMGN
Don't miss the next AMGN filing
- Alerts as it files. A push when AMGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AMGN, by share count.
- Ask anything. An AI agent that reads every AMGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Drake Michael V | A | Nov 6, 2026 | 114.026 | - |
| ISHRAK OMAR | A | Nov 6, 2026 | 152.035 | - |
| HOLLEY CHARLES M | A | Nov 6, 2026 | 184.614 | - |
| Gibbs David W | A | Nov 6, 2026 | 278 | - |
| Khosla Rachna | Sell | Aug 13, 2026 | 1,252 | $416.43 |
| Khosla Rachna | M | Aug 13, 2026 | 1,252 | - |
| Khosla Rachna | M | Aug 13, 2026 | 1,252 | $162.60 |
| Khosla Rachna | Sell | Aug 11, 2026 | 2,000 | $412.57 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $33.4B | $36.8B |
| Operating Income | - | $7.3B | $9.1B |
| Net Income | $6.7B | $4.1B | $7.7B |
| Op. Margin | - | 21.7% | 24.7% |
| Net Margin | - | 12.2% | 21.0% |
| Balance Sheet | |||
| Total Assets | $97.2B | $91.8B | $90.6B |
| Equity | - | $5.9B | $8.7B |
| ROE | - | 69.6% | 89.1% |
| Per Share | |||
| EPS | $12.49 | $7.56 | $14.23 |
| Cash Flow | |||
| Operating CF | - | $11.5B | $10.0B |
| CapEx | $1.1B | $1.1B | $1.9B |
Source: XBRL data in Amgen (AMGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AMGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 63 | $89.83B |
| Q2 2026 | 64 | $77.82B |
| Q1 2026 | 64 | $75.02B |
| Q4 2025 | 62 | $70.93B |
| Q3 2025 | 65 | $59.06B |
| Q2 2025 | 66 | $57.96B |
| Q1 2025 | 63 | $49.58B |
| Q4 2024 | 61 | $34.01B |
- JPMorgan Chase & Co+3.20M (+89%)
- T. Rowe Price Group+1.55M (+39%)
- State Street Corp+394.5K (+1%)
- Goldman Sachs Group+242.8K (+6%)
- Invesco Ltd+230.1K (+1%)
- Bank of America Corp−1.11M (-22%)
- D.E. Shaw & Co−884.5K (-69%)
- Two Sigma Investments−810.7K (-72%)
- BlackRock−436.2K (-1%)
- Wells Fargo & Co−296.8K (-4%)
- FMR LLC (Fidelity)−3.49M
- Equitable Holdings Inc−24.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 508 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AMGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 19, 2026 | - | Analysis | |
| SC 13G | May 14, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
AMGN SEC filings: frequently asked questions
Which institutions hold AMGN stock?
As of September 30, 2026, the largest Amgen (AMGN) holders among the 13F filers tracked by SignalX were BlackRock ($20.6 billion), Vanguard Capital Management LLC ($14.9 billion), State Street Corp ($13.0 billion), Invesco Ltd ($7.0 billion), Vanguard Portfolio Management LLC ($6.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AMGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Amgen (AMGN) reported revenue of $36.8 billion (up 10.0% from FY2024) and net income of $7.7 billion. Diluted EPS was $14.23. The figures come from the XBRL data in the 10-K.
What are the main risks in AMGN's latest 10-K?
In the 10-K filed February 13, 2026, Amgen (AMGN) flagged: Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages. Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals. (AI summary of the Risk Factors section.)
What did AMGN report in its latest 8-K?
Amgen (AMGN) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 unaudited results, plus September 30 financial position, announced November 3, 2026.
What are the latest AMGN SEC filings?
Amgen (AMGN) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 9, 2026.
What is AMGN's SEC CIK number?
Amgen (AMGN)'s SEC Central Index Key (CIK) is 318154. EDGAR lists every AMGN filing under that number.
Ask anything about AMGN
The research agent reads AMGN's filings, financials, insider trades and 13F holders, then answers with sources.